Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Ampio Pharmaceuticals ($AMPE) plans to delist from NYSE American, leading to a 37.5% pre-market drop. NeuBase Therapeutics ($NBSE) schedules a shareholder meeting on a dissolution plan, causing a 42.0% pre-market decline. PDS Biotechnology ($PDSB) focuses on late-stage clinical strategy for a triple combination in advanced head and neck cancer, abandoning a previous PDS0101-Keytruda combo study. The company raises $10.5M in Q4, with cash at $56.6M. Management's decision receives mixed reactions from shareholders and analysts.
Buyers today will be greatly rewarded. It really is a shame the disinformation and lies about $PDSB being spread by the likes of @adamfeuerstein @jfais20 @jacobplieth. They are either ignorant, poor journalists, have shorts in their pockets or maybe all 3. Due your research all.
$PDSB management clear focus here on which ph3 trial to initiate that saves time and money and one where phase 2 results (proof of concept data from ph2 trial run by NCI) outshines standard of care. Now adding IL-12ADC to the regimen should boost more efficacy. And people…
$PDSB When management shows, and tells, you who they are and what they are about, listen to them. https://t.co/XrzeNBNRdl
